Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).

2.50
Hdl Handle:
http://hdl.handle.net/10541/107534
Title:
Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).
Authors:
Bischoff, Helge G; Van den Borne, Ben; Pimentel, Francisco L; Arellano, Jorge; Langer, Frank; Leschinger, Monika I; Thatcher, Nick
Abstract:
OBJECTIVE: The ACTION (Assessment of Cost and ouTcomes of chemotherapy In an Observational setting) study investigated associations between chemotherapy, patient/disease characteristics and outcomes in advanced non-small cell lung cancer (NSCLC) patients in clinical practice. RESEARCH DESIGN AND METHODS: Chemonaïve NSCLC patients from five European countries were observed for 18 months from initiation of first-line chemotherapy; care was at the physician's discretion. MAIN OUTCOME MEASURES: Survival and associated prognostic factors were estimated using Kaplan-Meier methods and a Cox proportional hazards model, respectively. Cluster analyses of baseline patient characteristics were also performed. Toxicity data were not considered in these analyses. RESULTS: A total of 975 eligible patients with NSCLC (Stage IIIb/IV) were enrolled and provided baseline and response data; cluster analysis was performed on 829 patients and survival data were available from 906 patients. In first-line treatment, a 39.8% response rate, a 39.5% 1-year survival rate and unadjusted median survival of 9.3 months were observed. Prognostic factors for survival included performance status (PS), number of metastatic organs, gender and age. Five patient clusters were identified, highlighting patient heterogeneity in terms of baseline condition and age. PS was maintained or improved throughout first-line and second-line chemotherapy in half the patients receiving these treatments. CONCLUSIONS: ACTION provides valuable information about patient population, disease characteristics, treatment choices, prescribing patterns and outcomes in routine clinical practice in advanced NSCLC in Europe. Our findings suggest that maintenance of PS after first and subsequent lines of chemotherapy, and survival rates may both be higher than previously anticipated. Our results also showed an association between age and survival, which suggests that age should not exclude patients from receiving chemotherapy if they meet all other eligibility criteria.
Affiliation:
Thoraxklinik, Heidelberg, Germany. Helge.Bischoff@thoraxklinik-heidelberg.de
Citation:
Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). 2010, 26 (6):1461-70 Curr Med Res Opin
Journal:
Current medical research and opinion
Issue Date:
Jun-2010
URI:
http://hdl.handle.net/10541/107534
DOI:
10.1185/03007991003799180
PubMed ID:
20394472
Type:
Article
Language:
en
ISSN:
1473-4877
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBischoff, Helge Gen
dc.contributor.authorVan den Borne, Benen
dc.contributor.authorPimentel, Francisco Len
dc.contributor.authorArellano, Jorgeen
dc.contributor.authorLanger, Franken
dc.contributor.authorLeschinger, Monika Ien
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-13T09:20:55Z-
dc.date.available2010-07-13T09:20:55Z-
dc.date.issued2010-06-
dc.identifier.citationObservation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). 2010, 26 (6):1461-70 Curr Med Res Opinen
dc.identifier.issn1473-4877-
dc.identifier.pmid20394472-
dc.identifier.doi10.1185/03007991003799180-
dc.identifier.urihttp://hdl.handle.net/10541/107534-
dc.description.abstractOBJECTIVE: The ACTION (Assessment of Cost and ouTcomes of chemotherapy In an Observational setting) study investigated associations between chemotherapy, patient/disease characteristics and outcomes in advanced non-small cell lung cancer (NSCLC) patients in clinical practice. RESEARCH DESIGN AND METHODS: Chemonaïve NSCLC patients from five European countries were observed for 18 months from initiation of first-line chemotherapy; care was at the physician's discretion. MAIN OUTCOME MEASURES: Survival and associated prognostic factors were estimated using Kaplan-Meier methods and a Cox proportional hazards model, respectively. Cluster analyses of baseline patient characteristics were also performed. Toxicity data were not considered in these analyses. RESULTS: A total of 975 eligible patients with NSCLC (Stage IIIb/IV) were enrolled and provided baseline and response data; cluster analysis was performed on 829 patients and survival data were available from 906 patients. In first-line treatment, a 39.8% response rate, a 39.5% 1-year survival rate and unadjusted median survival of 9.3 months were observed. Prognostic factors for survival included performance status (PS), number of metastatic organs, gender and age. Five patient clusters were identified, highlighting patient heterogeneity in terms of baseline condition and age. PS was maintained or improved throughout first-line and second-line chemotherapy in half the patients receiving these treatments. CONCLUSIONS: ACTION provides valuable information about patient population, disease characteristics, treatment choices, prescribing patterns and outcomes in routine clinical practice in advanced NSCLC in Europe. Our findings suggest that maintenance of PS after first and subsequent lines of chemotherapy, and survival rates may both be higher than previously anticipated. Our results also showed an association between age and survival, which suggests that age should not exclude patients from receiving chemotherapy if they meet all other eligibility criteria.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectChemotherapyen
dc.subjectCancer Treatmenten
dc.subjectTreatment Outcomeen
dc.titleObservation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).en
dc.typeArticleen
dc.contributor.departmentThoraxklinik, Heidelberg, Germany. Helge.Bischoff@thoraxklinik-heidelberg.deen
dc.identifier.journalCurrent medical research and opinionen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.